Tolcapone
COMT inhibition for the treatment of Parkinson's disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The articles in this supplement are based in part on the findings from a Special Session held during the 4th International Congress on Movement Disorders, which took place in Vienna, Austria from June 16-21, 1996. This special symposium, COMT Inhibition with Tolcapone in the Treatment of Parkinson's Disease, was chaired by Professor Werner Poewe, Universitatsklinic für Neurologie, Innsbruck, Austria, and Christopher G. Goetz, MD, Professor of Neurological Sciences, Associate Chairperson, Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois. Several other articles in this supplement are original works that will provide the reader with knowledge about the pharmacokinetics and use of tolcapone in fluctuating and nonfluctuating Parkinson's patients. Indeed, this supplement is a compilation of much of the pivotal clinical data on tolcapone.
A new class of drugs, catechol O-methyltrasferase (COMT) inhibitors, has shown promise for treating PD in Phase III clinical studies. In patients receiving levodopa, most (about 70%) of the orally administered levodopa is metabolized rapidly by peripheral dopa decarboxylase to dopamine, which is further metabolized by intracellular monoamine …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
COMT Inhibition for the Treatment of Parkinson's Disease: Articles
COMT inhibitionA new treatment strategy for Parkinson's diseaseMatthias C. Kurth, Charles H. Adler et al.Neurology, May 01, 1998 -
Treatment Guidelines
Management of Parkinson's diseaseet al.Neurology, March 01, 1998 -
Articles
The comparative effects of medical therapies for Parkinson’s diseaseStacy Horn, Matthew B. Stern et al.Neurology, October 18, 2004 -
COMT Inhibition for the Treatment of Parkinson's Disease: Articles
Levodopa therapyConsequences of the nonphysiologic replacement of dopamineThomas N. Chase et al.Neurology, May 01, 1998